Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities
Net loss	$ (11,168,449)	$ (10,168,116)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	700,276	603,480
Accretion of discount on NuvoGen obligation	(6,656)	(6,483)
Provision for excess inventory	1,672	45,000
Amortization of QNAH Convertible Note issuance costs	6,505	6,727
Amortization of MidCap Credit Facility discount and issuance costs	101,482	81,096
Amortization of SVB Term Loan discount and issuance costs	3,389
Stock-based compensation expense	776,793	528,578
Employee stock purchase plan expense	10,758	33,589
Non-cash operating lease expense	306,230	194,232
Accrued interest on available-for-sale securities investments	(98,092)	(178,165)
Issuance of common stock in connection with LP Purchase Agreement	205,538
Loss on extinguishment of Midcap Credit Facility and QNAH Convertible Note	522,394
Loss on abandonment of assets	49,226
Changes in operating assets and liabilities:
Accounts receivable	2,152,714	1,031,575
Inventory	(120,575)	100,927
Prepaid expenses and other	171,774	(501,474)
Deferred offering costs	140,320
Accounts payable	(659,736)	1,172,992
Accrued liabilities	(1,047,223)	(1,784,860)
Contract liabilities	(53,284)	344,494
Operating lease liabilities	(378,840)	(270,477)
Net cash used in operating activities	(8,383,784)	(8,766,885)
Investing activities
Purchase of property and equipment	(322,372)	(319,425)
Sales, redemptions and maturities of available-for-sale securities	17,950,000	22,400,000
Purchase of available-for-sale securities	(4,272,298)	(9,290,341)
Net cash provided by investing activities	13,355,330	12,790,234
Financing activities
Proceeds from issuance of SVB Term Loan and common stock warrants	10,000,000
Payment of SVB Term Loan issuance costs	(45,934)
Proceeds from ATM Offering, net	3,830,970
Proceeds from PPP Loan	1,717,000
Proceeds from Series A convertible preferred stock in private placement	562,955
Payments on NuvoGen obligation	(421,525)	(655,855)
Proceeds from exercise of pre-funded warrants	31,768
Proceeds from shares purchased under stock purchase plans	25,133	82,345
Proceeds from exercise of stock options		120,954
Payments on financing leases	(22,845)	(25,227)
Taxes paid for net share settlement of restricted stock awards	(9,160)	(20,837)
Payment of deferred offering costs		(139,058)
Payments on Insurance Note	(80,710)
Net cash provided by (used in) financing activities	5,149,029	(637,678)
Effect of exchange rates on cash	3,805	(4,682)
Increase in cash, cash equivalents and restricted cash	10,124,380	3,380,989
Cash, cash equivalents and restricted cash at beginning of period	10,889,995	11,702,847
Cash, cash equivalents and restricted cash at end of period	21,014,375	15,083,836
Supplemental disclosure of noncash investing and financing activities
Issuance of Series A convertible preferred stock in exchange for outstanding common stock	2,424,900
Issuance of Common stock in exchange for Series A convertible preferred stock	1,622,500
Adoption of ASC 842, Leases		694,352
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	21,078	894,544
Fixed asset purchases payable and accrued at period end		374,202
SVB Term Loan costs payable and accrued at period end	60,710
Supplemental cash flow information
Cash paid for interest	602,200	348,130
Cash paid for taxes	6,581	$ 6,848
QNAH Convertible Note
Financing activities
Payments for extinguishment of debt	(3,000,000)
MidCap Credit Facility
Financing activities
Payments for extinguishment of debt	$ (7,438,623)